Revvity (RVTY) Competitors

Revvity has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

In the previous week, Revvity had 2 more articles in the media than Bio-Techne. MarketBeat recorded 6 mentions for Revvity and 4 mentions for Bio-Techne. Revvity's average media sentiment score of 0.25 beat Bio-Techne's score of 0.07 indicating that Revvity is being referred to more favorably in the media.

Revvity presently has a consensus price target of $116.57, indicating a potential downside of 22.75%. Bio-Techne has a consensus price target of $68.92, indicating a potential downside of 4.82%. Given Bio-Techne's higher probable upside, analysts clearly believe Bio-Techne is more favorable than Revvity.

Bio-Techne has a net margin of 14.97% compared to Revvity's net margin of 8.16%. Bio-Techne's return on equity of 13.23% beat Revvity's return on equity.

Revvity has higher revenue and earnings than Bio-Techne. Bio-Techne is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

86.7% of Revvity shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Comparatively, 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Revvity pays out 13.3% of its earnings in the form of a dividend. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Revvity currently has a consensus price target of $116.57, suggesting a potential downside of 22.75%. Agilent Technologies has a consensus price target of $170.33, suggesting a potential upside of 1.87%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Revvity.

Agilent Technologies has higher revenue and earnings than Revvity. Agilent Technologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

In the previous week, Agilent Technologies had 5 more articles in the media than Revvity. MarketBeat recorded 11 mentions for Agilent Technologies and 6 mentions for Revvity. Agilent Technologies' average media sentiment score of 0.29 beat Revvity's score of 0.25 indicating that Agilent Technologies is being referred to more favorably in the news media.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.6%. Revvity pays out 13.3% of its earnings in the form of a dividend. Agilent Technologies pays out 20.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Revvity has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

86.7% of Revvity shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Agilent Technologies has a net margin of 19.53% compared to Revvity's net margin of 8.16%. Agilent Technologies' return on equity of 24.45% beat Revvity's return on equity.

In the previous week, Bio-Rad Laboratories and Bio-Rad Laboratories both had 6 articles in the media. Bio-Rad Laboratories' average media sentiment score of 0.62 beat Revvity's score of 0.25 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Bio-Rad Laboratories has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Revvity has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Bio-Rad Laboratories has a net margin of 8.59% compared to Revvity's net margin of 8.16%. Revvity's return on equity of 8.34% beat Bio-Rad Laboratories' return on equity.

65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bio-Rad Laboratories currently has a consensus price target of $343.33, suggesting a potential downside of 5.93%. Revvity has a consensus price target of $116.57, suggesting a potential downside of 22.75%. Given Bio-Rad Laboratories' higher possible upside, equities analysts plainly believe Bio-Rad Laboratories is more favorable than Revvity.

Bio-Rad Laboratories has higher earnings, but lower revenue than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Revvity has a net margin of 8.16% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Revvity's return on equity.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revvity has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

In the previous week, Charles River Laboratories International had 5 more articles in the media than Revvity. MarketBeat recorded 11 mentions for Charles River Laboratories International and 6 mentions for Revvity. Charles River Laboratories International's average media sentiment score of 0.91 beat Revvity's score of 0.25 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Revvity currently has a consensus target price of $116.57, indicating a potential downside of 22.75%. Charles River Laboratories International has a consensus target price of $300.11, indicating a potential upside of 4.13%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, analysts plainly believe Charles River Laboratories International is more favorable than Revvity.

Revvity has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.